The association of serotonin transporter genotypes and selective serotonin reuptake inhibitor (SSRI)-associated sexual side effects: Possible relationship to oral contraceptives

Human Psychopharmacology

Volumn 24, Issue 3, 2009, Pages 207-215

  Bishop, Jeffrey R ^a   Ellingrod, Vicki L ^b   Akroush, Michael ^a   Moline, Jessica ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Antidepressant; Polymorphism; Serotonin transport; Sexual dysfunction

Indexed keywords

CITALOPRAM; ESCITALOPRAM; ESTROGEN; FLUOXETINE; GESTAGEN; ORAL CONTRACEPTIVE AGENT; PAROXETINE; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SLC6A4 PROTEIN, HUMAN;

ADULT; ARTICLE; CONFIDENCE INTERVAL; DEPRESSION; FEMALE; GENE DELETION; GENE INSERTION; GENOTYPE; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; PROMOTER REGION; QUESTIONNAIRE; SEXUAL DYSFUNCTION; VARIABLE NUMBER OF TANDEM REPEAT; WELLBEING; ADOLESCENT; CHEMICALLY INDUCED DISORDER; GENETIC VARIABILITY; GENETICS; RISK; SEXUAL DEVELOPMENT;

ADOLESCENT; ADULT; CONFIDENCE INTERVALS; CONTRACEPTIVES, ORAL; DEPRESSION; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; MALE; MINISATELLITE REPEATS; ODDS RATIO; PROMOTER REGIONS, GENETIC; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; SEX CHARACTERISTICS; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; YOUNG ADULT;

EID: 67649695972     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1006     Document Type: Article

References (34)

1. Battersby S, Ogilvie AD, Smith CA, et al. 1996. Structure of a variable number tandem repeat of the serotonin transporter gene and association with affective disorder. Psychiatr Genet 6: 177-181.
2. Benmansour S, Piotrowski JP, Altamirano AV, Frazer A. 2009. Impact of ovarian hormones on the modulation of the serotonin transporter by fluvoxamine. Neuropsychopharmacology 34: 555-564.
3. Bethea CL, Pecins-Thompson M, Schutzer WE, Gundlah C, Lu ZN. 1998. Ovarian steroids and serotonin neural function. Mol Neurobiol 18: 87-123.
4. Bishop JR, Moline J, Ellingrod VL, Schultz SK, Clayton AH. 2006. Serotonin 2A -1438 G/A and G-protein Beta3 subunit C825T polymorphisms in patients with depression and SSRI-associated sexual side-effects. Neuropsychopharmacology 31: 2281-2288.
5. Bradley SL, Dodelzon K, Sandhu HK, Philibert RA. 2005. Relationship of serotonin transporter gene polymorphisms and haplotypes to mRNA transcription. Am J Med Genet B Neuropsychiatr Genet 136: 58-61.
6. Bull SA, Hunkeler EM, Lee JY, et al. 2002. Discontinuing or switching selective serotonin-reuptake inhibitors. Ann Pharmacother 36: 578-584.
7. Clayton A, Keller A, McGarvey EL. 2006. Burden of phase-specific sexual dysfunction with SSRIs. J Affect Disord 91: 27-32.
8. Clayton AH. 2002. Female sexual dysfunction related to depression and antidepressant medications. Current Women's Health Reports 2: 182-187.
9. Clayton AH, McGarvey EL, Clavet GJ. 1997a. The Changes in Sexual Functioning Questionnaire (CSFQ): development, reliability, and validity. Psychopharmacol Bull 33: 731-745.
10. Clayton AH, McGarvey EL, Clavet GJ, Piazza L. 1997b. Comparison of sexual functioning in clinical and nonclinical populations using the Changes in Sexual Functioning Questionnaire (CSFQ). Psychopharmacol Bull 33: 747-753.
11. Clayton AH, Owens JE, McGarvey EL. 1995. Assessment of paroxetine-induced sexual dysfunction using the Changes in Sexual Functioning Questionnaire. Psychopharmacol Bull 31: 397-413.
12. Clayton AH, Pradko JF, Croft HA, et al. 2002. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 63: 357-366.
13. Cyr M, Bosse R, Di Paolo T. 1998. Gonadal hormones modulate 5-hydroxytryptamine2A receptors: emphasis on the rat frontal cortex. Neuroscience 83: 829-836.
14. Fiskerstrand CE, Lovejoy EA, Quinn JP. 1999. An intronic polymorphic domain often associated with susceptibility to affective disorders has allele dependent differential enhancer activity in embryonic stem cells. FEBS Lett 458: 171-174.
15. Heils A, Teufel A, Petri S, et al. 1996. Allelic variation of human serotonin transporter gene expression. J Neurochem 66: 2621-2624.
16. Keller A, McGarvey EL, Clayton AH. 2006. Reliability and construct validity of the Changes in Sexual Functioning Questionnaire short form (CSFQ-14). J Sex Marital Ther 91: 43-52.
17. Laumann EO, Paik A, Rosen RC. 1999. Sexual dysfunction in the United States: prevalence and predictors. JAMA 281: 537-544.
18. MacKenzie A, Quinn J. 1999. A serotonin transporter gene intron 2 polymorphic region, correlated with affective disorders, has allele-dependent differential enhancer-like properties in the mouse embryo. Proc Natl Acad Sci U S A 96: 15251-15255.
19. Meston CM, Frohlich PF. 2000. The neurobiology of sexual function. Arch Gen Psychiatry 57: 1012-1030.
20. Montejo-Gonzalez AL, Llorca G, Izquierdo JA, et al. 1997. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther 23: 176-194.
21. Montejo AI, Llorca G, Izquierdo JA, et al. 1996. Sexual dysfunction secondary to SSRIs. A comparative analysis in 308 patients. Actas Luso-Esp de Neurol Psiquiatr Cienc Afines 24: 311-321.
22. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. 2001a. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the study of psychotropic-related sexual dysfunction. J Clin Psychiatry 62 (Suppl 3): 10-21.
23. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. 2001b. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction [see comment]. J Clin Psychiatry 62 (Suppl 3): 10-21.
24. Murray JB. 1998. Physiological mechanisms of sexual dysfunction side effects associated with antidepressant medication. J Psychol 132: 407-416.
25. Ogilvie AD, Battersby S, Bubb VJ, et al. 1996. Polymorphism in serotonin transporter gene associated with susceptibility to major depression. Lancet 347: 731-733.
26. Pecins-Thompson M, Brown NA, Bethea CL. 1998. Regulation of serotonin re-uptake transporter mRNA expression by ovarian steroids in rhesus macaques. Brain Res Mol Brain Res 53: 120-129.
27. Philibert RA, Sandhu H, Hollenbeck N, Gunter T, Adams W, Madan A. 2008. The relationship of 5HTT (SLC6A4) methylation and genotype on mRNA expression and liability to major depression and alcohol dependence in subjects from the Iowa Adoption Studies. Am J Med Genet B Neuropsychiatr Genet 147B(5): 543-549.
28. Popp J, Leucht S, Heres S, Steimer W. 2006. Serotonin transporter polymorphisms and side effects in antidepressant therapy - a pilot study. Pharmacogenomics 7: 159-166.
29. Richards B, Skoletsky J, Shuber AP, et al. 1993. Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal brushes/ swabs. Hum Mol Genet 2: 159-163.
30. Serretti A, Kato M, De Ronchi D, Kinoshita T. 2007. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry 12: 247-257.
31. Smits K, Smits L, Peeters F, et al. 2007. Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 22: 137-143.
32. Stahl SM. 1998. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord 51: 215-235.
33. Wendland JR, Martin BJ, Kruse MR, Lesch KP, Murphy DL. 2006. Simultaneous genotyping of four functional loci of human SLC6A4, with a reappraisal of 5-HTTLPR and rs25531. Mol Psychiatry 11: 224-226.
34. Wihlback AC, Sundstrom Poromaa I, Bixo M, Allard P, Mjorndal T, Spigset O. 2004. Influence of menstrual cycle on platelet serotonin uptake site and serotonin2A receptor binding. Psychoneuroendocrinology 29: 757-766.